pdf   xlsx method abbreviations

Extensive stage SCLC (Es-SCLC), immune chekpoint inhibitors versus placebo, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.88 [0.76, 1.01]< 10%2 studies (2/-)96.6 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.69 [0.61, 0.79]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
objective responses (ORR) 2.63 [1.57, 4.39]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

TRAE (any grade) 2.50 [0.90, 6.96]< 194%2 studies (2/-)4.0 %some concernnot evaluable moderatenon important-
TRAE (grade 3-4) 4.47 [0.59, 33.57]< 197%2 studies (2/-)7.4 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 3.27 [0.50, 21.53]< 119%2 studies (2/-)11.0 %some concernnot evaluable moderatenon important-
TRAE leading to discontinuation (any grade) 35.24 [11.93, 104.09]< 114%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.